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PURPOSE / OBJECTIVE(s)

RESULTS

Response rates for unresectable and/or
metastatic sarcomas are generally poor with
most patients progressing on systemic
therapy.1
In this setting, conventional palliative radiation
therapy (RT) provides both limited tumor
control and symptom relief.2
Recent studies suggest that aggressive local
therapy, such as surgery and/or RT, may
improve oncologic outcomes.3,4
Given the relative radioresistance of sarcomas
and their often large size, dose escalated,
hypofractionated (HF) RT may improve
oncologic outcomes over traditional RT.
We Investigated the efficacy of HFRT in
improving survival outcomes, palliation, and
duration of systemic therapy breaks in patients
with sarcoma.
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HFRT is an effective treatment strategy for
patients with unresectable or metastatic
sarcoma to provide durable TLC, symptom
relief, and meaningful systemic therapy breaks
with limited toxicity.

MATERIALS & METHODS

Patients with unresectable or oligometastatic/progressive disease benefited from
longer systemic therapy breaks and lower rates
of distant relapse.

With IRB approval, we retrospectively reviewed
73 consecutive patients with sarcoma who
received >10 fractions of HFRT from 20172020.
HFRT was delivered most commonly using
intensity modulated radiation therapy (IMRT)
with a simultaneous integrated boost to further
escalate the dose.
The rationale for HFRT included the
following clinical scenarios :
1. palliative/symptomatic (34%)
2. an unresectable primary (27%)
3. oligometastatic disease (16%)
4. oligoprogressive disease (23%)
Oligometasatic disease was defined as < 5
sites of metastasis based on CT or PET
imaging.
Oligoprogressive disease was defined as a
limited sites of progressive disease in patients
with otherwise stable metastatic disease.

CONCLUSIONS

The 1-year disease specific survival was 59%, which was more favorable for
patients receiving HFRT for oligometastatic (1-y 100%) or oligoprogressive (1-y
73%) disease (P=0.001).
The 1-y targeted lesional control (TLC) was 73% with 26% developing
progression at a median time of 7.5 m (IQR, 5.5-13).
A metastatic target (1-y 95% vs 60% primary, P=0.02; HR 0.27, P=0.04) and soft
tissue origin (1-y 78% vs 61% bone, P=0.01; HR 0.33, P=0.02) were associated
with better TLC on univariate and multivariable analyses.
For patients not planned for adjuvant systemic therapy (n=53), the median
systemic therapy break was 9 m (IQR, 4-23), and notably longer in
oligometastatic (13 m), oligoprogressive (12 m) or unresectable (13 m) disease.
The rate of distant failure was high with a 6-month DMFS of only 43%. HFRT
use for unresectable (P<0.001, HR 0.14) and oligometastatic (P=0.003, HR 0.25)
disease were the only factors associated with improved DMFS on multivariable
analysis.

If overall disease control is the primary goal for
HFRT, patient selection remains crucial as
distant relapse is high.
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